Phase I clinical safety and efficacy observation of αPD-1-mesoCAR-T cells in the treatment of advanced gynecologic cancer.
Yong Xia(Jiading District Central Hospital), Qijun Qian(Shanghai University), Xinhong Guan(Shanghai University), Yaping Yang(Shanghai Cell Therapy Research Institute), Yuying Sun(Shanghai Cell Therapy Research Institute), Yanyan Yu(Shanghai University), Zhongzheng Zhu(Tongji University), Linjie Lv(Shanghai Cell Therapy Research Institute), Zongchang Song(Shanghai University), Hui Xue(Shanghai University), Zhi‐Feng Miao(Kaohsiung Medical University), Zhong Li(Nanjing Forestry University), Sitong Wang(Shanghai Cell Therapy Research Institute), Zhuqing Liu(Northeast Agricultural University), Qing Xu(Shanghai Tenth People's Hospital), Yan Sun(Shanghai Cell Therapy Research Institute), Zhicai Lin(Shanghai Cell Therapy Research Institute), Jinxing Lou(Shanghai University)
Cited by 0
Related Papers
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
|Signal Transduction and Targeted Therapy|2019|699
Updating the East Asian mtDNA phylogeny: a prerequisite for the identification of pathogenic mutations
|Human Molecular Genetics|2006|390
CD133: a stem cell biomarker and beyond
|Experimental Hematology and Oncology|2013|340
Non-coding RNAs participate in the regulatory network of CLDN4 via ceRNA mediated miRNA evasion
|Nature Communications|2017|268